Rachel Vatnsdal
Stock Analyst at JP Morgan
(2.03)
# 1,847
Out of 4,479 analysts
35
Total ratings
38.89%
Success rate
-3.37%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $165 → $155 | $125.78 | +23.23% | 5 | May 30, 2024 | |
| RGEN Repligen | Maintains: Overweight | $230 → $200 | $120.14 | +66.47% | 3 | May 2, 2024 | |
| NVST Envista Holdings | Maintains: Overweight | $29 → $23 | $16.34 | +40.76% | 1 | May 2, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $600 → $650 | $533.93 | +21.74% | 7 | Apr 25, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | n/a | $1.28 | - | 1 | Apr 22, 2024 | |
| AKYA Akoya Biosciences | Maintains: Overweight | $12 → $10 | $2.18 | +358.72% | 1 | Mar 6, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $82 → $88 | $65.60 | +34.15% | 2 | Mar 6, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $11 → $8 | $3.37 | +137.39% | 1 | Feb 15, 2024 | |
| BRKR Bruker | Upgrades: Overweight | $60 → $90 | $61.64 | +46.01% | 2 | Feb 14, 2024 | |
| DHR Danaher | Maintains: Overweight | $250 → $270 | $240.41 | +12.31% | 4 | Dec 20, 2023 | |
| WAT Waters | Maintains: Neutral | $260 → $250 | $284.49 | -12.12% | 2 | Nov 8, 2023 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $14 | $24.76 | -43.46% | 2 | Nov 7, 2023 | |
| RVTY Revvity | Maintains: Neutral | $130 → $110 | $102.01 | +7.83% | 2 | Oct 17, 2023 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,300 → $1,100 | $1,357.07 | -18.94% | 1 | Oct 17, 2023 | |
| CTLT Catalent | Downgrades: Neutral | $90 → $45 | $56.20 | -19.93% | 1 | May 22, 2023 |
Agilent Technologies
May 30, 2024
Maintains: Overweight
Price Target: $165 → $155
Current: $125.78
Upside: +23.23%
Repligen
May 2, 2024
Maintains: Overweight
Price Target: $230 → $200
Current: $120.14
Upside: +66.47%
Envista Holdings
May 2, 2024
Maintains: Overweight
Price Target: $29 → $23
Current: $16.34
Upside: +40.76%
Thermo Fisher
Apr 25, 2024
Maintains: Overweight
Price Target: $600 → $650
Current: $533.93
Upside: +21.74%
Pacific Biosciences of California
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Akoya Biosciences
Mar 6, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.18
Upside: +358.72%
Henry Schein
Mar 6, 2024
Maintains: Overweight
Price Target: $82 → $88
Current: $65.60
Upside: +34.15%
Adaptive Biotechnologies
Feb 15, 2024
Maintains: Overweight
Price Target: $11 → $8
Current: $3.37
Upside: +137.39%
Bruker
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $61.64
Upside: +46.01%
Danaher
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $240.41
Upside: +12.31%
Waters
Nov 8, 2023
Maintains: Neutral
Price Target: $260 → $250
Current: $284.49
Upside: -12.12%
Myriad Genetics
Nov 7, 2023
Maintains: Underweight
Price Target: $17 → $14
Current: $24.76
Upside: -43.46%
Revvity
Oct 17, 2023
Maintains: Neutral
Price Target: $130 → $110
Current: $102.01
Upside: +7.83%
Mettler-Toledo International
Oct 17, 2023
Maintains: Neutral
Price Target: $1,300 → $1,100
Current: $1,357.07
Upside: -18.94%
Catalent
May 22, 2023
Downgrades: Neutral
Price Target: $90 → $45
Current: $56.20
Upside: -19.93%